Trial Condition(s):
Renal Cell Carcinoma
Duration of treatment with tyrosine kinase inhibitors in the treatment of metastatic renal cell carcinoma (TURCOS)
Bayer Identifier:
16263
ClinicalTrials.gov Identifier:
EudraCT Number:
Not Available
EU CT Number:
Not Available
Trial Purpose
This study is a prospective, non-interventional, non-controlled, multi-center, observational cohort study. The medication is prescribed within the regular practice of the physician. Duration and dosage of treatment is solely at the discretion of the attending physician. The primary objective of this study is to assess duration of treatment in Turkish renal cell carcinoma patients treated with TKIs (Tyrosine Kinase Inhibitors) who could not tolerate prior cytokine treatment within the first month of treatment.
Inclusion Criteria
- To be diagnosed as metastatic renal cell carcinoma - Previous cytokine therapy - To sign informed consent form (ICF)
Exclusion Criteria
- Patients not willing to sign informed consent form or who withdraw their consent
Trial Summary
Enrollment Goal
Trial Dates
Phase
Could I receive a placebo?
Products
Accepts Healthy Volunteers
Where to Participate
| Locations | Status | |
|---|---|---|
Locations Investigative Site Many Locations, Turkey | Status Completed | Contact Us: E-mail: [email protected] Phone: Not Available |
Trial Design
Duration of treatment with TKIs in the treatment of Metastatic Renal Cell Carcinoma
Trial Type:
Observational
Intervention Type:
Other
Trial Purpose:
N/A
Allocation:
N/A
Blinding:
N/A
Assignment:
N/A
Trial Arms:
1
Primary Outcome
- Duration of treatment: from start of tyrosine kinase inhibitor treatment to permanent discontinuation of the productTimeframe: After 2 years
Secondary Outcome
- Incidence of treatment-emergent adverse events (TEAE)Timeframe: After 2 years
- Change of Tumor statusTimeframe: Baseline and 2 years
Additional Information
Copyright © Bayer
Powered by
